GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.
The webinar will feature CEO Michael Breen and Dr. Jeffrey Miller, MD, Consulting Senior Medical Director, who will discuss clinical progress in blood cancers and solid tumors, insights from increasing dose levels, the platform’s competitive positioning, and key milestones ahead.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology.
GTBP shares leaped $1.19, or 19.2%, to $7.37.
Related Stories
